Response Genetics's Days Sales Outstanding for the
three
months ended in Dec. 2015 was 0.
Response Genetics's Days Inventory for the
three
months ended in Dec. 2015 was 0.
Response Genetics's Days Payable for the
three
months ended in Dec. 2015 was 0.
Therefore, Response Genetics's Cash Conversion Cycle (CCC) for the
three
months ended in Dec. 2015 was 0.00.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Response Genetics Cash Conversion Cycle Related Terms
Response Genetics Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Response Genetics's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RGDXQ vs PSID, GBSN, ETAH: Cash Conversion Cycle Comparison
For the Diagnostics & Research subindustry, Response Genetics's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Response Genetics Cash Conversion Cycle vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Response Genetics's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Response Genetics's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Response Genetics's Cash Conversion Cycle for the fiscal year that ended in Dec. 2015 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Response Genetics (RGDXQ) has a Cash Conversion Cycle of 0.00 as of Dec. 2015. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Response Genetics and its competitors.
Is Response Genetics' Cash Conversion Cycle too high?
Response Genetics' current Cash Conversion Cycle is 0.00.
How does Response Genetics' Cash Conversion Cycle compare to PSID and GBSN?
Response Genetics' Cash Conversion Cycle of 0.00 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Cash Conversion Cycle is 74.74. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Diagnostics & Research company?
The median Cash Conversion Cycle among Medical Diagnostics & Research companies is 74.74, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Response Genetics and its competitors. For the Medical Diagnostics & Research industry, the median Cash Conversion Cycle is 74.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Response Genetics's current Cash Conversion Cycle is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Response Genetics stock overvalued right now?
Response Genetics (RGDXQ) has a current Cash Conversion Cycle of 0.00. The current Cash Conversion Cycle is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Response Genetics (RGDXQ), the current Cash Conversion Cycle is 0.00 as of Dec. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGDXQ has been successfully added to your 